Progression

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)

Affecting up to 5% of the global population, SLD represents an area of significant unmet medical need with limited treatment...

Lancet study has hope for liver cancer: Immunotherapy drug can delay progression in patients who can’t be treated with surgery | Health and Wellness News

Immunotherapy, a form of treatment that uses the body’s immune system to find and fight cancer cells, can delay the...